CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 604 enrolled
Drug / intervention
AN2690 Topical Solution, 5% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01302119
NCT01302119Phase 3Completed

A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults

Pfizer·interventional·Posted Feb 23, 2011·Updated Apr 3, 2019

In Brief

A Phase 3 clinical trial evaluating AN2690 Topical Solution, 5% and Solution Vehicle for Onychomycosis of Toenails. Completed, enrolled 604 participants across 32 sites in 2 countries.

Detailed Summary

The purpose of this study is to determine whether AN2690 topical solution is a safe and effective treatment for onychomycosis of the toenail.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 23, 2011
Enrollment StartFeb 1, 2011
Primary CompletionDec 31, 2012
Study CompletionFeb 20, 2013
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 15.4 years ago

Interventions

AN2690 Topical Solution, 5%drug

AN2690 Topical Solution, 5%, applied once daily for 48 weeks

Solution Vehicledrug

AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks